Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study
about
Testosterone deficiency in the aging maleOutcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinologyEffects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studiesChallenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials.Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.Testosterone and weight loss: the evidence.Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men.Testosterone supplementation therapy in the treatment of patients with metabolic syndrome.Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss.Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years.Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome.A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel.Testosterone replacement therapy and bone mineral density in men with hypogonadism.Injectable testosterone undecanoate for the treatment of hypogonadism.Testosterone and obesity.Update on Testosterone Replacement Therapy in Hypogonadal Men.Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups.Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model.Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study).Low Testosterone in Men with Cardiovascular Disease or Risk Factors: To Treat or Not To Treat?Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: effects of 3 years intermittent testosterone supplementation.Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss.Effects of testosterone replacement therapy on bone metabolism in male post-surgical hypogonadotropic hypogonadism: focus on the role of androgen receptor CAG polymorphism.Trials of testosterone replacement reporting cardiovascular adverse events.Hypogonadal men with psoriasis benefit from long-term testosterone replacement therapy - a series of 15 case reports.Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update.Testosterone is associated with age-related changes in bone health status, muscle strength and body composition in menGender in Endocrine Diseases: Role of Sex Gonadal Hormones
P2860
Q26770414-9EB8AF7A-7D82-4305-80D8-035A53B131F5Q26864777-2EEBEBBA-3CC1-4843-AB71-7D5D385A4BB2Q30983590-CBB2552E-EFAE-40A8-B5FF-E0D86788326DQ31099075-4F653D39-A1D2-41B7-BEDE-C956C45DD8CDQ31111735-B6E61226-ABF7-4918-9ADF-085235B10738Q34134273-0CE480C2-90F8-4D8A-BD77-7E980987ECB3Q36287950-872CD230-4C59-427B-BB66-2262A4FC87C7Q37088526-7171E74A-E1B5-49A7-95C0-1F3739614007Q37235722-DA2AEFE4-BDCF-4274-B96F-084DA4E0AA3EQ37618825-E7762A65-8E6A-47B7-9AE4-74850C91F94AQ37622016-093C6C53-49EE-4DDE-96F0-FBFEDB319A45Q37641683-7C512DDD-6789-4743-AAE7-BD1A92192AD9Q37673421-FE23AF34-1B58-4871-9604-EFF306CC9135Q38235669-CC101B2F-B26B-4059-9BE0-81A096D42AD7Q38485746-BA1D6CCF-CACA-4F74-B80D-4A0A013FF515Q38528376-42B10FAB-42E5-43E3-BBEC-B8FDDE0B04DBQ38830965-799AD551-C4EA-46CE-907A-4C44BFB9CE57Q38857929-7CA8E944-A534-4641-9EF4-A97162D00F29Q38873488-C9876DED-9AFA-4B8D-BFF8-0AE5C2DA95CDQ38997207-756EC6A1-BFBF-433C-8E9F-2FDAAF8F990FQ42174870-1C1D72E2-B293-45EA-8D02-7E98FCB3AA70Q44245579-E8FDF804-5F1E-45B9-A919-7726E6D21A19Q44619585-C48BD474-2D50-4C4F-9F8C-C14E8AC385B6Q47571312-984837C0-119C-4ED6-A97E-F6EE510715C3Q52864351-C905032C-8825-4355-AFFE-28CB92E848A5Q53100434-86838F7B-FB2E-41D1-830F-54A2F0574293Q58276088-6A70CF45-DCD9-4527-97FC-F6F050BA56A1Q58695108-5901CEE8-75DE-4093-A5E4-BEBD42649371
P2860
Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study
description
im März 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 23 March 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2012
@uk
name
Effects of long-acting testost ...... m a 36 months controlled study
@en
Effects of long-acting testost ...... m a 36 months controlled study
@nl
type
label
Effects of long-acting testost ...... m a 36 months controlled study
@en
Effects of long-acting testost ...... m a 36 months controlled study
@nl
prefLabel
Effects of long-acting testost ...... m a 36 months controlled study
@en
Effects of long-acting testost ...... m a 36 months controlled study
@nl
P2093
P2860
P50
P1433
P1476
Effects of long-acting testost ...... m a 36 months controlled study
@en
P2093
Luigi Di Luigi
Rachele Fornari
Roberto Bruzziches
P2860
P304
P356
10.3109/13685538.2011.631230
P577
2012-03-23T00:00:00Z